However, anticoagulant reversal is unquestionably required in specific situations including urgent invasive procedures, overdose, or life-threatening traumatic or spontaneous bleeding. The short half-life of DOACs compared with warfarin obviates the use of an antidote in most cases. Major bleeding occurs annually in 1% to 3% of DOAC-treated patients and results in high mortality.
1 The results of this study question whether these antidotes fulfill an unmet need and improve DOAC-treated patient outcomes. Recently, after the publication of the ANNEXA-4 study, andexanet alfa, the antidote for factor Xa (FXa) inhibitors, was approved. Idarucizumab was marketed in 2018 for the reversal of the thrombin inhibitor dabigatran. Nevertheless, the fear of bleeding owing to the lack of a specific antidote has been a major concern.
Customer Service and Ordering Informationĭirect oral anticoagulants (DOAC) are recommended as the preferred option for the treatment and prevention of thromboembolic events because of a favorable benefit–risk profile when compared with vitamin K antagonists.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
